Pain treatment options for osteoarthritis

Česká verzia

Authors: Olga Šléglová
Authors place of work: Revmatologický ústav, Praha
Published in the journal: Vnitř Lék 2023; 69(2): 119-127
Category: Review Articles
doi: https://doi.org/10.36290/vnl.2023.019

Summary

Osteoarthritis is one of the most common diseases of the joints and spine and is characterized by degenerative changes starting in the cartilage. Joint changes cause pain, stiffness, swelling, and a loss of normal joint function. Several international recommendations address the choice of treatment methods for osteoarthritis. However, because there is still no effective causal treatment leading to a remission of the disease, this is a complex issue. Even the possibilities of effective but safe treatment of pain, which is the most common problem accompanying osteoarthritis, are very limited.

All current international recommendations for the treatment of osteoarthritis agree on the crucial role of non-pharmacological treatment and the choice of a comprehensive approach to the treatment of osteoarthritis. Pharmacological treatment includes non-opioid analgesics, opioids, symptomatic slow-acting osteoarthritis drugs, or intra-articular corticosteroids. A new trend is to maximize the potential of existing analgesics by combining them. Using drugs from different classes with complementary mechanisms of action provides a better opportunity for effective analgesia at reduced doses of individual agents. The use of fixed combinations is also advantageous.

Keywords:

osteoarthritis – Analgesics – intra‑articular corticosteroids – non‑steroidal antirheumatic drugs – symptomatic slow‑acting drugs for osteoarthritis

Zdroje

1. Cisternas MG, Murphy L, Sacks JJ, Solomon DH, et al. Alternative Methods for Defining Osteoarthritis and the Impact on Estimating Prevalence in a US Population‑Based Survey. Arthritis Care Res (Hoboken). 2016;68(5):574-580.

2. Pavelka K, Olejárová M. Osteoatróza. In: Pavelka K, Vencovský J, Horák P, et al. Revmatologie. Maxdorf, Praha 2018:556-594. ISBN 978-80-7345-583-5.

3. Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Rheumatol. 2020;72(2):220-233.

4. Bannura RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non‑surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis and Cartilage. 2019;27:1578-1589.

5. Bruyere O, Honvoa G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49:337-350.

6. Kloppenburg M, Kroon FPB, Blanco FJ, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum, DiS. 2019;78:16-24.

7. Pavelka K. Doporučení České revmatologické společnosti pro léčbu osteoartrózy kolenních, kyčelních a ručních kloubů. Čes Revmatol. 2012;3:138-156.

8. Fernandes L, Hagen KB, Bijlsma JWJ, et al. EULAR recommendations for the non‑pharmacological core management of hip and knee osteoarthritis. Ann Rheum, DiS. 2013;72:1125-1135.

9. Forejtová S. Systémová nesteroidní antirevmatika. In: Pavelka K, Vencovský J, Šenolt L, et al. Farmakoterapie revmatických onemocnění. Maxdorf, Praha 2017: 33-41. ISBN 978-80-7345-537-8.

10. Derry S, Moore RA, Gaskell H, McIntyre M, Wiffen PJ. Topical NSAIDs for acute musculoskeletal pain in adults. Cochrane Database Syst Rev. 2015; CD007402.

11. Derry S, Moore RA, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2012;9:CD007400.

12. Derry S, Moore RA, Rabbie R. Topical NSAIDs for chronic musculoskeletal pain in adults. Cochrane Database Syst Rev. 2016; CD007400.

13. Rannou F, Pelletier JP, Martel‑Pelletier J. Efficacy and safety of topical NSAIDs in the management of osteoarthritis: evidence from real‑life setting trials and surveys. Semin Arthritis Rheum. 2016;45(4Suppl):S18-21.

14. Lejčko J, Kozák J, Fricová J, et al. Metodické pokyny pro farmakoterapii bolesti. Bolest. 2016;19 suppl.1:1-27.

15. Toupin AK, Bisaillon J, Welch V, et al. Tramadol for osteoarthritis. Cochrane Database Syst Rev. 2019;27:CD005522.

16. Pergolizzi JV jr., van de Laar M, Langford R, et al. Tramadol/paracetamol fixed‑dose combination in the treatment of moderate to severe pain. J Pain Res. 2012;5:327-346.

17. Moore RA, Gay‑Escoda C, Figueiredo R, et al. Dexketoprofen/tramadol: randomised double‑blind trial and confirmation of empirical theory of combination analgesics in acute pain. J Headache Pain. 2015;16:541-8.

18. Chou R, Turner JA, Devine EB, et al. The effectiveness and risks of long‑term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med. 2015;162:276-86.

19. Dowell D, Haegerich TM, Choi R. CDC Gudelines for prescribing opioids for chronic pain. United States, 2016. Recommendations and reports. 2016;65(1):1-49.

20. Wang ZY, Shi SY, Li SJ, et al. Efficacy and safety of duloxetine on osteoarthritis knee pain: a meta‑analysis of randomized controlled trials. Pain Med. 2015;16(7):1373-1385.